a sublingual cyclobenzaprine treatment for fibromyalgia. The study met its primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005), and demonstrated statistically ...

The company's lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant ...

The most challenging part of my recent pain journey was the uncertainty. But, as uncomfortable as it is, uncertainty also ...

[6] The authors stated that two-month treatment with trazodone ... statistically significant effect on fibromyalgia severity, depression, anxiety and pain interference with daily activities ...

Investors interested in arranging a meeting with the Company’s management virtually during the conference should contact the Investor Summit conference coordinator. A live webcast of the presentation ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

Chances are, you or someone you care about is living with persistent or chronic pain, often defined as pain that lasts for ...

CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical ...

A delay in antibiotic treatment can make the disease more difficult to treat and may result in chronic symptoms and pain, so ...

Detailed price information for Neurometrix Inc (NURO-Q) from The Globe and Mail including charting and trades.

The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE) - ...